AIGH Capital Management LLC Lowers Stock Position in Delcath Systems, Inc. (NASDAQ:DCTH)

AIGH Capital Management LLC cut its stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 81.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 260,719 shares of the company's stock after selling 1,124,670 shares during the quarter. Delcath Systems makes up about 1.4% of AIGH Capital Management LLC's portfolio, making the stock its 22nd largest position. AIGH Capital Management LLC owned approximately 0.78% of Delcath Systems worth $3,319,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of DCTH. Charles Schwab Investment Management Inc. bought a new position in Delcath Systems during the fourth quarter worth $156,000. Quantbot Technologies LP bought a new position in Delcath Systems during the fourth quarter worth $66,000. EntryPoint Capital LLC bought a new position in Delcath Systems during the fourth quarter worth $299,000. Diametric Capital LP boosted its stake in Delcath Systems by 39.6% during the fourth quarter. Diametric Capital LP now owns 94,737 shares of the company's stock worth $1,141,000 after acquiring an additional 26,881 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Delcath Systems by 14.7% during the fourth quarter. Geode Capital Management LLC now owns 288,951 shares of the company's stock worth $3,481,000 after acquiring an additional 37,056 shares in the last quarter. 61.12% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on DCTH. HC Wainwright reissued a "buy" rating and set a $29.00 target price (up from $24.00) on shares of Delcath Systems in a research note on Friday, May 23rd. Wall Street Zen downgraded shares of Delcath Systems from a "buy" rating to a "hold" rating in a report on Saturday, July 5th. Finally, Stephens restated an "overweight" rating and set a $25.00 price objective on shares of Delcath Systems in a report on Monday, June 23rd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $24.00.

Delcath Systems Price Performance

Shares of NASDAQ DCTH traded down $0.24 during trading on Tuesday, hitting $11.08. The stock had a trading volume of 523,876 shares, compared to its average volume of 452,913. Delcath Systems, Inc. has a 12 month low of $7.17 and a 12 month high of $18.23. The company has a market capitalization of $385.87 million, a PE ratio of -22.16 and a beta of 0.87. The firm has a fifty day moving average of $14.59 and a two-hundred day moving average of $13.83.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.07). The firm had revenue of $19.80 million during the quarter, compared to the consensus estimate of $16.83 million. Delcath Systems had a negative return on equity of 29.44% and a negative net margin of 26.38%. On average, equities analysts expect that Delcath Systems, Inc. will post -0.79 earnings per share for the current fiscal year.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.